Ursula Nestle

Dr. Ursula Nestle


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
UNUrsula Nestle
Ursula Nestle
DRDirk De Ruysscher
Dirk De Ruysscher
URUmberto Ricardi
Umberto Ricardi
XGXavier Geets
Xavier Geets
JBJose Belderbos
Jose Belderbos
PHPaul Van Houtte
Paul Van Houtte

1 April 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
UNUrsula Nestle
Ursula Nestle
TSTanja Schimek-Jasch
Tanja Schimek-Jasch
SKStephanie Kremp
Stephanie Kremp
ASAndrea Schaefer-Schuler
Andrea Schaefer-Schuler
MMMichael Mix
Michael Mix
BKB Krause
B Krause

22 May 2024 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
ALAntonin Levy
Antonin Levy
SASonja Adebahr
Sonja Adebahr
CHCoen Hurkmans
Coen Hurkmans
MAMerina Ahmed
Merina Ahmed
SAShahreen Ahmad
Shahreen Ahmad
UNUrsula Nestle
Ursula Nestle

15 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MCMontserrat Carles
Montserrat Carles
TFTobias Fechter
Tobias Fechter
GRGianluca Radicioni
Gianluca Radicioni
TSTanja Schimek-Jasch
Tanja Schimek-Jasch
SASonja Adebahr
Sonja Adebahr
EGEleni Gkika
Eleni Gkika
The aim of this study is to identify clinically relevant image feature (IF) changes during chemoradiation and evaluate their efficacy in predicting treatment response. Patients with non-small-cell lung cancer (NSCLC) were enrolled in two prospective trials (STRIPE, PET-Plan). We evaluated 48 patients who underwent static (3D) and retrospectively-respiratory-gated 4D PET/CT scans before treatment and a 3D scan during or after treatment. Our proposed method rejects IF changes due to intrinsic variability. The IF variability observed across 4D PET is employed as a patient individualized normalization factor to emphasize statistically relevant IF changes during treatment. Predictions of overall survival (OS), local recurrence (LR) and distant metastasis (DM) were evaluated. From 135 IFs, only 17 satisfied the required criteria of being normally distributed across 4D PET and robust between 3D and 4D images. Changes during treatment in the area-under-the-curve of the cumulative standard-uptake-value histogram (δAUCCSH) within primary tumor discriminated (AUC = 0.87, Specificity = 0.78) patients with and without LR. The resulted prognostic model was validated with a different segmentation method (AUC = 0.83) and in a different patient cohort (AUC = 0.63). The quantification of tumor FDG heterogeneity by δAUCCSH during chemoradiation correlated with the incidence of local recurrence and might be recommended for monitoring treatment response in patients with NSCLC.

9 August 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DBDominik Bettinger
Dominik Bettinger
EGEleni Gkika
Eleni Gkika
MSMichael Schultheiss
Michael Schultheiss
NGNicolas Glaser
Nicolas Glaser
SLSophie Lange
Sophie Lange
TBThomas Brunner
Thomas Brunner
As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced HCC. Patients treated with TACE (n = 367) and patients allocated to SBRT (n = 35) were enrolled in this study. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics of TACE and SBRT patients. Local tumor control (LC) 1 year after treatment, overall survival (OS) and 1-year mortality were assessed. Patients treated with SBRT have received more prior HCC treatments compared to TACE patients. The LC 1 year after treatment in the unmatched cohort was 74.4% for TACE patients compared to 84.8% in the SBRT group. Patients treated with TACE showed significantly improved OS (17.0 months vs. 9.0 months, p = 0.016). After propensity score matching, the LC in the TACE (n = 70) and SBRT (n = 35) group was comparable (82.9% vs. 84.8%, p = 0.805) and OS did not differ significantly in both groups. SBRT after prior HCC therapy in selected patients shows comparable LC at 1 year, OS and 1-year mortality compared to patients treated with TACE.

1 October 2018 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
MLMarie Lambrecht
Marie Lambrecht
JSJan-Jakob Sonke
Jan-Jakob Sonke
UNUrsula Nestle
Ursula Nestle
HPHeike Peulen
Heike Peulen
DWDamien Charles Weber
Damien Charles Weber
CHCoen W. Hurkmans
Coen W. Hurkmans
Extensive radiation therapy quality assurance (RTQA) programs are needed when advanced radiotherapy treatments are used. As part of the RTQA four dimensional computed tomography (4DCT) imaging performance needs to be assessed. Here we present the RTQA data related to 4DCT procedures used within the context of stereotactic body radiotherapy (SBRT) of centrally located lung tumours. It provides an overview of the 4DCT acquisition methods and achievable accuracy of imaging lung tumour volumes. 3DCT and 4DCT images were acquired from a CIRS phantom with spheres of 7.5 and 12.5 mm radius using the institutional scan protocols. Regular asymmetric tumour motion was simulated with varying amplitudes and periods. Target volumes were reconstructed using auto-contouring with scanner specific thresholds. Volume and amplitudes deviations were assessed. Although acquisition parameters were rather homogeneous over the eleven institutions analysed, volume deviations were observed. Average volume deviations for the 12.5 mm sphere were 15% (−4% to 69%) at end of inspiration, 2% (−2% to 9.0%) at end of expiration and 12% (0% to 36%) at mid-ventilation. For the 7.5 mm sphere deviations were 13% (−99% to 65%), 16% (−34% to 66%) and 1% (−13% to 20%), respectively. The amplitude deviation was generally within 2 mm although underestimations up to 6 mm were observed. The expiration phase was the most accurate phase to define the tumour volume and should be preferred for GTV delineation of tumours exhibiting large motion causing motion artefacts when using mid-ventilation or tracking techniques. The large variation found among the institutions indicated that further improvements in 4DCT imaging were possible. Recommendations for 4DCT QA have been formulated.